GNH USA

Europe — EMA

Mresvia

GNH USA supplies Mresvia (RSV mRNA), a vaccine for prevention of respiratory syncytial virus infection. Request a quote for worldwide supply to hospitals.

Single-Stranded 5' Capped Mrna Encoding The Respiratory Syncytial Virus Glycoprotein F Stabilized In

Request sourcing

1
Pack/s

What is Single-Stranded 5' Capped Mrna Encoding The Respiratory Syncytial Virus Glycoprotein F Stabilized In?

Single-Stranded 5' Capped mRNA encoding RSV F glycoprotein, the active ingredient in Mresvia, is a vaccine presented as an injectable solution for intramuscular use. It is intended to prevent respiratory syncytial virus infection in individuals at risk, such as infants, older adults, and immunocompromised patients.

GNH USA supplies Mresvia as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

What is Single-Stranded 5' Capped Mrna Encoding The Respiratory Syncytial Virus Glycoprotein F Stabilized In used for?

Mresvia is a respiratory syncytial virus (RSV) vaccine used to stimulate immunity against RSV infection.

Infants: reduces the risk of severe RSV disease and hospitalization. Older adults: lowers incidence of RSV‑related lower respiratory tract infection. Immunocompromised patients: provides protective immunity against RSV exposure.

What are the side effects of Single-Stranded 5' Capped Mrna Encoding The Respiratory Syncytial Virus Glycoprotein F Stabilized In?

Common Side Effects: - Injection‑site pain or tenderness. - Redness or swelling at the injection site. - Low‑grade fever. - Headache. - Fatigue or malaise. - Muscle aches.

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction. - Guillain‑Barré syndrome. - Myocarditis or pericarditis. - Thrombocytopenia. - Neurological events such as seizures. - Severe local inflammation or abscess formation.

What precautions apply to Single-Stranded 5' Capped Mrna Encoding The Respiratory Syncytial Virus Glycoprotein F Stabilized In?

Before administration, consider the following precautions: - Screening: assess individual risk for RSV and prior vaccine reactions. - Contraindication: avoid in persons with known severe allergy to any vaccine component. - Pregnancy: safety not established; use only if benefit outweighs risk. - Breastfeeding: unknown safety; weigh potential benefits. - Immunocompromised patients: monitor immune response and possible reduced efficacy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Single-Stranded 5' Capped Mrna Encoding The Respiratory Syncytial Virus Glycoprotein F Stabilized In interact with?

Vaccines may interact with other agents that modify immune response.

Major Interactions (Avoid): - Concurrent administration of live attenuated vaccines. - Immunoglobulin or blood products within 4 weeks of vaccination. - High‑dose corticosteroids given at the time of vaccination.

Moderate Interactions (Monitor Closely): - Antipyretics may mask post‑vaccination fever. - Immunosuppressive therapy may reduce vaccine efficacy. - Antiviral agents targeting RSV may interfere with immune priming. - Seasonal influenza vaccine given within 2 weeks may affect antibody titres.

Frequently asked questions

What is Mresvia used for?+
Mresvia is a vaccine designed to prevent infection by respiratory syncytial virus (RSV). It is administered by intramuscular injection and is intended for individuals at risk of severe RSV disease, including infants, older adults, and immunocompromised patients.
How does the RSV mRNA in Mresvia work?+
The product contains a single‑stranded, 5'‑capped mRNA that encodes the RSV F glycoprotein. After injection, host cells translate the mRNA into the F protein, which is recognized by the immune system, prompting the production of neutralising antibodies and cellular immunity that protect against future RSV exposure.
What is the usual dose of Mresvia?+
The dose and schedule of Mresvia are determined by the prescribing healthcare professional based on the patient’s age, health status, and local immunisation guidelines. No fixed regimen is provided here; the prescriber sets the appropriate regimen.
Is Mresvia safe during pregnancy or breastfeeding?+
Safety data for Mresvia in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.
How do I order Mresvia from GNH USA?+
To place an order, submit an enquiry on the Mresvia product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.
How does Mresvia compare with other RSV vaccines?+
Mresvia uses an mRNA platform that delivers the RSV F glycoprotein directly to host cells, whereas many other RSV vaccines rely on recombinant protein or live‑attenuated virus approaches. The mRNA technology can induce both humoral and cellular immunity and may offer manufacturing advantages, but comparative efficacy and safety depend on clinical trial data for each product.
What are the storage and handling requirements for Mresvia?+
Mresvia must be stored refrigerated at 2‑8 °C. Keep the vials in the original packaging, protect them from light, and avoid freezing or shaking. Follow cold‑chain procedures during transport to maintain product integrity.
How is Mresvia administered?+
Mresvia is given as an intramuscular injection, typically into the deltoid muscle of the upper arm. The injection should be performed by a qualified healthcare professional using aseptic technique and the appropriate needle size for the patient’s age and body weight.
What are the most serious risks associated with Mresvia?+
Serious adverse events, although rare, can include anaphylaxis, Guillain‑Barré syndrome, myocarditis, thrombocytopenia, and severe neurological reactions. Patients should be observed after vaccination and seek immediate medical attention if they experience signs of a severe allergic reaction or neurological symptoms.
Who should not receive Mresvia?+
Mresvia is contraindicated in individuals with a known severe allergy to any component of the vaccine. It should also be used with caution in pregnant or breastfeeding women, and in patients receiving high‑dose immunosuppressive therapy, where the immune response may be diminished.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Single-Stranded 5' Capped Mrna Encoding The Respiratory Syncytial Virus Glycoprotein F Stabilized In
Route
Intramuscular Use
Manufacturer
Moderna Biotech Spain S. L.
Origin
EU